Lawyers and Settlements
Home Page >> Saxagliptin marketed as Onglyza and Kombiglyze XR >> Articles

Onglyza and Kombiglyze XR Articles

‘Failure to Warn’ at Heart of Onglyza Lawsuits

‘Failure to Warn’ at Heart of Onglyza Lawsuits December 31, 2017. By Anne Wallace.
San Francisco, CA: Once the procedural wrangling is over, the argument that patients were hurt because drug manufacturers, AstraZeneca and Bristol-Meyers Squibb, failed to warn them of the dangers of Onglyza side effects will be at the heart of the Onglyza lawsuits.
Read [ ‘Failure to Warn’ at Heart of Onglyza Lawsuits ]

Onglyza Lawsuits Seek MDL Status in California

Onglyza Lawsuits Seek MDL Status in California November 4, 2017. By Anne Wallace.
San Francisco, CA: On October 11, 2017, a group of Onglyza plaintiffs filed a Motion to Transfer with the U.S. Judicial Panel on Multidistrict Litigation (JPML). The motion seeks to consolidate the Onglyza lawsuits filed throughout the federal court system in the U.S. District Court for the Northern District of California. At the time of filing, there were 44 lawsuits pending in 24 federal jurisdictions, all of which put forth virtually identical legal and factual theories. Plaintiffs foresee the possibility that hundreds of Onglyza and Kombiglyze (collectively referred to as “Onglyza” in the motion) lawsuits will be filed in the future.
Read [ Onglyza Lawsuits Seek MDL Status in California ]

Add Pancreatic Cancer to Your List of Saxagliptin Worries

Add Pancreatic Cancer to Your List of Saxagliptin Worries October 9, 2017. By Anne Wallace.
Washington, DC: While patient lawsuits have focused on the danger of heart failure as a Saxagliptin side effect, the risk of pancreatic cancer may be flying under the radar. It can be just as deadly, and research suggests a link between Saxagliptin and the disease.
Read [ Add Pancreatic Cancer to Your List of Saxagliptin Worries ]

Despite Concerns over Onglyza, FDA Keeps Going Back to the Trough

Despite Concerns over Onglyza, FDA Keeps Going Back to the Trough September 6, 2017. By Gordon Gibb.
Washington, DC: In the accepted parlance of the pharmaceutical and medical industries, a drug is considered not unsafe for the intended patient if the benefits of the drug outweigh the risk. One can therefore assume that the US Food and Drug Administration (FDA) took this mantra to heart in 2009 when the federal regulator approved Onglyza (saxagliptin) in spite of reservations over potential saxagliptin side effects and the results of clinical trials associated with Onglyza conducted before the drug was approved.
Read [ Despite Concerns over Onglyza, FDA Keeps Going Back to the Trough ]

California Saxagliptin Lawsuit Plaintiffs Score Big Procedural Win

California Saxagliptin Lawsuit Plaintiffs Score Big Procedural Win August 11, 2017. By Anne Wallace.
Washington, DC:Saxagliptin lawsuit plaintiffs just got a big victory. The fact that they can sue in California courts under California law will affect whether and how much they can recover for the injuries they have suffered.
Read [ California Saxagliptin Lawsuit Plaintiffs Score Big Procedural Win ]

Onglyza, Kombiglyze Maintain Risks in Spite of Dismissed Lawsuits

Onglyza, Kombiglyze Maintain Risks in Spite of Dismissed Lawsuits July 22, 2017. By Gordon Gibb.
Trenton, NJ: Plaintiffs bringing either a saxagliptin lawsuit, or an Onglyza lawsuit (Onglyza is the trade name for saxagliptin) appear to have had a checkered track record in terms of success with their cases in spite of various side effects associated with the Type 2 diabetes drug.
Read [ Onglyza, Kombiglyze Maintain Risks in Spite of Dismissed Lawsuits ]

New Jersey Man Claims Diabetes Medicine Caused His Heart Disease

New Jersey Man Claims Diabetes Medicine Caused His Heart Disease June 27, 2017. By Deb Hipp.
Trenton, NJ: A New Jersey man has filed a federal lawsuit against drug manufacturers Bristol-Myers Squibb and Astrazeneca Pharmaceuticals, claiming he suffered injuries after taking the diabetes drug Saxagliptin, sold under the brand names Onglyza and Kombiglyze XR.
Read [ New Jersey Man Claims Diabetes Medicine Caused His Heart Disease ]

New Lawsuit Claims Drug Manufacturers Failed to Warn of Risks of Diabetes Medication

New Lawsuit Claims Drug Manufacturers Failed to Warn of Risks of Diabetes Medication March 28, 2017. By Deb Hipp.
Dallas, TX:A federal lawsuit filed recently over a popular diabetes medication claims that drug manufacturers failed to warn consumers of heart attack risks associated with the drug.
Read [ New Lawsuit Claims Drug Manufacturers Failed to Warn of Risks of Diabetes Medication ]

FDA to Add Heart Failure Warnings to DPP-4 Type 2 Diabetes Medications

FDA to Add Heart Failure Warnings to DPP-4 Type 2 Diabetes Medications April 6, 2016. By Lucy Campbell.
Washington, DC: Type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, according to a recent safety review by the US Food and Drug Administration (FDA).
Read [ FDA to Add Heart Failure Warnings to DPP-4 Type 2 Diabetes Medications ]

Onglyza Lawsuit Alleges Heart Failure Caused by Drug

Onglyza Lawsuit Alleges Heart Failure Caused by Drug November 15, 2015. By Heidi Turner.
Chicago, IL: An Onglyza lawsuit has been filed against AstraZeneca, alleging the diabetes drug caused a woman’s death. The lawsuit was filed late in October, according to reports, and claims that Lillie Ree Gibson died from heart problems after taking Onglyza.
Read [ Onglyza Lawsuit Alleges Heart Failure Caused by Drug ]